Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + AK104 + Bevacizumab in Recurrent/Persistent Clear Cell Ovarian Cancer
NCT06540729Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2024
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin, cadonilimab, bevacizumab in ovarian clear cell carcinoma (OCCC), sponsored by Sun Yat-sen Memorial Hospital. Started Sep 2024; status: recruiting.
02
Drugs
disitamab vedotincadonilimabbevacizumab
03
Conditions
ovarian clear cell carcinoma (OCCC)
Beyond the preview
Go deeper on NCT06540729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06540729.